← Leaderboards
Lance R McMahon
University Of Florida
$14,694,531
Attributed
$20,498,951
Total exposure
9
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.7M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,498,951 · 9
By mechanism
R01$11,227,579 · 4
UH3$4,479,677 · 1
UG3$3,574,538 · 1
UC2$767,554 · 1
R21$438,000 · 1
P51$11,603 · 1
Top collaborators
- Christopher R Mccurdy14 shared
Most similar at University Of Florida
Same institution · by research overlap
- Christopher R McCurdy$12,051,179
- Abhisheak Sharma$212,097
- Julie A Marusich$2,280,423
Others in their field
Top investigators on “Agonist”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- Alan G. Barbour · University Of California Irvine$40,092,035
- Alexandros Makriyannis · University Of Connecticut Storrs$29,942,402
- Scott T Weiss · University Of California, San Diego$28,624,344
- John Didsbury · T3d Therapeutics, Inc.$25,150,614
Research focus
AgonistStimulusDrug DiscriminationReceptorPharmacotherapyPharmaceutical PreparationsBehavioralDoseChronicIn VivoAttenuatedPharmacologyBaseOpioidBehavioral AssayMacaca MulattaWithdrawalDependenceAdrenergic AgonistsIn VitroFundingUnited StatesLigandsBinding
Grant awards (45)
The Future of Rural Health: Accelerating Biomedical Excellence at TTUHSC$380,054
UC2 · FY2025 · MD · contact PI
The Future of Rural Health: Accelerating Biomedical Excellence at TTUHSC$387,500
UC2 · FY2024 · MD · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$1,444,681
UH3 · FY2023 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$705,717
R01 · FY2023 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$72,690
R01 · FY2023 · DA
Opioid use disorders: UF Pharmacy medications discovery and development$1,444,681
UH3 · FY2022 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$693,433
R01 · FY2022 · DA
Opioid use disorders: UF Pharmacy medications discovery and development$72,817
UH3 · FY2022 · DA
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$72,690
R01 · FY2022 · DA
Opioid use disorders: UF Pharmacy medications discovery and development$1,444,681
UH3 · FY2021 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$681,503
R01 · FY2021 · DA
Opioid use disorders: UF Pharmacy medications discovery and development$72,817
UH3 · FY2021 · DA · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$1,551,049
UG3 · FY2020 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$669,920
R01 · FY2020 · DA · contact PI
Opioid use disorders: UF Pharmacy medications discovery and development$2,023,489
UG3 · FY2019 · DA · contact PI
Kratom alkaloids: in vitro and in vivo pharmacological mechanisms$658,673
R01 · FY2019 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$343,125
R01 · FY2018 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$172,164
R01 · FY2017 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$170,730
R01 · FY2017 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$375,284
R01 · FY2016 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$331,329
R01 · FY2015 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$42,700
R01 · FY2015 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$336,375
R01 · FY2014 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$342,251
R01 · FY2013 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$308,027
R01 · FY2013 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$356,511
R01 · FY2012 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$320,861
R01 · FY2012 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$356,511
R01 · FY2011 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$320,861
R01 · FY2011 · DA · contact PI
Pharmacotherapy of Cannabinoid Withdrawal: Pre-Clinical Studies$371,250
R01 · FY2010 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$367,538
R01 · FY2010 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$330,784
R01 · FY2010 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$371,250
R01 · FY2009 · DA · contact PI
Pharmacotherapy of Cannabinoid Withdrawal: Pre-Clinical Studies$346,833
R01 · FY2009 · DA · contact PI
Nicotine dependence: neuropharmacology in monkeys$333,656
R01 · FY2009 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$339,164
R01 · FY2008 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$346,086
R01 · FY2007 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$356,423
R01 · FY2006 · DA · contact PI
TREATMENT OF CANNABINOID WITHDRAWAL IN RHESUS MONKEYS$11,603
P51 · FY2006 · RR · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$3,240
R01 · FY2006 · DA · contact PI
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$365,000
R01 · FY2005 · DA
Drug discrimination and THC withdrawal in monkeys$146,000
R21 · FY2005 · DA
Treatment of Cannabinoid Withdrawal in Rhesus Monkeys$365,000
R01 · FY2004 · DA
Drug discrimination and THC withdrawal in monkeys$146,000
R21 · FY2004 · DA
Drug discrimination and THC withdrawal in monkeys$146,000
R21 · FY2003 · DA